Pediatric Dyslipidemia and Screening Recommendations

Published:September 08, 2021DOI:https://doi.org/10.1016/j.nurpra.2021.08.009

      Highlights

      • Pediatric dyslipidemia affects approximately 20% of children ages 6 to 19.
      • Familial hypercholesterolemia affects 1 in 200 to 500 individuals.
      • Pediatric atherosclerosis leads to early cardiovascular complications in early adulthood.
      • Screening recommendations are inconsistent.
      • The literature is lacking long-term patient outcomes related to treatment.

      Abstract

      Pediatric dyslipidemia affects approximately 20% of children ages 6 to 19 years. This disease is impacted by and contributes to many factors, including obesity, metabolic syndrome, diabetes, and hypothyroidism. Obesity doubles the risk of dyslipidemia, but 26% to 63% of normal-weight children have lipid abnormalities. Dyslipidemia contributes to pediatric onset of atherosclerotic changes, and early adult cardiovascular complications. Sedentary lifestyle and poor food choices are the primary causes, but familial hypercholesterolemia affects 1 in 200 to 500 individuals. Evidence-based guidelines and screening recommendations are inconsistent among disciplines, there is poor compliance with utilization, and treatment options lack long-term outcome data.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal

      Subscribe:

      Subscribe to The Journal for Nurse Practitioners
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • United States Preventive Services Task Force
        Screening for lipid disorders in children and adolescents: US Preventive Services Task Force recommendation statement.
        JAMA. 2016; 316: 625-633https://doi.org/10.1001/jama.2016.9852
        • de Ferranti S.D.
        • Newburger J.W.
        Dyslipidemia in children: definition, screening, and diagnosis.
        UpToDate. 2021;
        • Nguyen D.
        • Kit B.
        • Carroll M.
        Abnormal cholesterol among children and adolescents in the United States, 2011-2014 (data brief no. 228).
        National Center for Health Statistics, 2015
        • Stewart J.
        • McCallin T.
        • Martinez J.
        • Chacko S.
        • Yusuf S.
        Hyperlipidemia.
        Pediatr Rev. 2020; 41: 393-403https://doi.org/10.1542/pir.2019-0053
        • Lozano P.
        • Henrikson N.B.
        • Dunn J.
        • et al.
        Lipid screening in childhood and adolescence for detection of familial hypercholesterolemia: evidence report and systematic review for the US Preventive Services Task Force.
        JAMA. 2016; 316: 645-655https://doi.org/10.1001/jama.2016.6176
        • Urbina E.M.
        • de Ferranti S.D.
        Lipid screening in children and adolescents [editorial].
        JAMA. 2016; 316: 589-591https://doi.org/10.1001/jama.2016.9671
        • Zawacki A.W.
        • Enright C.
        • Harris R.E.
        • Dodge A.
        • Peterson A.L.
        Clinician responses to pediatric lipid screens suggestive of severe dyslipidemia.
        J Pediatr X. 2020; 4: 100037https://doi.org/10.1016/j.ympdx.2020.100037
        • de Ferranti S.D.
        • Steinberger J.
        • Ameduri R.
        • et al.
        Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association.
        Circulation. 2019; 139: e603-e634https://doi.org/10.1161/CIR.000000000000061
        • Perak A.M.
        • Ning H.
        • Kit B.K.
        • et al.
        Trends in levels of lipids and apolipoprotein B in US youths aged 6 to 19 years, 1999-2016).
        JAMA. 2019; 321: 1895-1905https://doi.org/10.1001/jama.2019.4984
        • Bendor C.D.
        • Bardugo A.
        • Pinhas-Hamiel O.
        • Afek A.
        • Twig G.
        Cardiovascular morbidity, diabetes, and cancer risk among children and adolescents with severe obesity.
        Cardiovasc Diabetol. 2020; 19: 79https://doi.org/10.1186/s12933-020-01052-1
        • Fornari E.
        • Maffeis C.
        Treatment of metabolic syndrome in children.
        Front Endocrinol (Lausanne). 2019; 10: 702https://doi.org/10.3389/fendo.2019.00702
        • Herrington L.
        • Gorman G.
        • Nylund C.M.
        • Hisle-Gorman E.
        Factors affecting pediatric dyslipidemia screening and treatment.
        Clin Pediatr. 2019; 58: 502-510https://doi.org/10.1177/0009922819832068
        • Sunil B.
        • Ashra A.P.
        Dyslipidemia in pediatric type 2 diabetes mellitus.
        Curr Diab Rep. 2020; 20: 53https://doi.org/10.1007/s11892-020-01336-6
        • Vukovic R.
        • Zeljkovic A.
        • Bufan B.
        • Spasojevic-Kalimanovska V.
        • Milenkovic T.
        • Vekic J.
        Hashimoto thyroiditis and dyslipidemia in childhood: a review.
        Front Endocrinol (Lausanne). 2019; 10: 868https://doi.org/10.3389/fendo.2019.00868
        • Kaufman T.K.
        • Gentile N.
        • Kumar S.
        • et al.
        Impact of point-of-care decision support tool on laboratory screening for comorbidities in children with obesity.
        Children. 2020; 7: 67https://doi.org/10.3390/children7070067
        • Sirvastava G.
        • Fox C.K.
        • Kelly A.S.
        • et al.
        Clinical considerations regarding the use of obesity pharmacotherapy in adolescents with obesity.
        Obesity. 2019; 27: 190-204https://doi.org/10.1002/oby.23385
        • Skinner A.C.
        • Perrin E.M.
        • Skelton J.A.
        Cardiometabolic risks and obesity in the young.
        N Engl J Med. 2016; 374: 592-593https://doi.org/10.1056/NEJMc1513890
        • Zachariah J.P.
        • Shittu T.
        • Wang Y.
        Lipid temporal trends in normal-weight youth.
        Am Heart J. 2020; 231: 68-72https://doi.org/10.1016/j.ahj.2020.10.050
        • Spurr S.
        • Bally J.
        • Hill P.
        • Gray K.
        • Newman P.
        • Hutton A.
        Exploring the prevalence of undiagnosed prediabetes, type 2 diabetes mellitus, and risk factors in adolescents: a systematic review.
        J Pediatr Nurs. 2020; 50: 94-104https://doi.org/10.1016/j.pedn.2019.09.025
        • Flisiak-Jackiewicz M.
        • Lebensztejn
        Update on pathogenesis, diagnosis, and therapy of nonalcoholic fatty liver disease in children.
        Clin Exp Hepatol. 2019; 5: 11-21https://doi.org/10.5114/ceh.2019.83152
        • Divers J.
        • Mayer-Davis E.J.
        • Lawrence J.M.
        • et al.
        Trends in incidence of type 1 and type 2 diabetes among youths-selected counties and Indian Reservations, United States, 2002-2015.
        MMWR Morb Mortal Wkly Rep. 2020; 69: 161-165
        • Xiong J.
        • Long J.
        • Chen X.
        • Li Y.
        • Song H.
        Dyslipidemia might be associated with an increased risk of osteoarthritis.
        Biomed Res Int. 2020; 2020: 3105248https://doi.org/10.1155/2020/3105248
        • Unal E.
        • Akin A.
        • Yildirim R.
        • Demir V.
        • Yildiz I.
        • Haspolat Y.K.
        Association of subclinical hypothyroidism with dyslipidemia and increased carotid intima-media thickness in children.
        J Clin Res Pediatr Endocrinol. 2017; 9: 144-149https://doi.org/10.4274/jcrpe.3719
        • de Ferranti S.D.
        • Rodday A.M.
        • Parsons S.K.
        • et al.
        Cholesterol screening and treatment practices and preferences: a survey of United States Pediatricians.
        J Pediatr. 2017; 185: 99-105https://doi.org/10.1016/j.peds.2016.12.078
        • Sleeth C.M.
        • Peterson A.L.
        • Hokanson J.
        Pediatric dyslipidemia screening by pediatricians and family medicine physicians: current practices and future directions.
        Pediatrics. 2020; 146: 636-637https://doi.org/10.1052/peds.146.1_MeetingAbstract.636
        • Gourgari E.
        • Dabelea D.
        • Rother K.
        Modifiable risk factors for cardiovascular disease in children with type 1 diabetes: can early intervention prevent future cardiovascular events?.
        Curr Diab Rep. 2017; 17: 134https://doi.org/10.1007/s11892-017-0968-y
        • Smith A.J.
        • Turner E.L.
        • Kinra S.
        • Bodurtha J.N.
        • Chien A.T.
        A cost analysis of universal versus targeted cholesterol screening in pediatrics.
        J Pediatr. 2018; 196: 201-207https://doi.org/10.1016/j.peds.2018.01.027
        • Burns C.E.
        • Dunn A.M.
        • Brady M.A.
        • Starr N.B.
        • Blosser C.G.
        • Garson D.L.
        Pediatric Primary Care.
        7th ed. Elsevier, 2021
      1. Hagan J.F. Shaw J.S. Duncan P.M. Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents. 4th ed. American Academy of Pediatrics, 2017
        • Valaiyapathi B.
        • Sunil B.
        • Ashraf A.P.
        Approach to hypertriglyceridemia in the pediatric population.
        Pediatr Rev. 2017; 38: 424-434https://doi.org/10.1542/pir.2016-0138
        • Jellinger P.S.
        • Handelsman Y.
        • Rosenbilt P.D.
        • et al.
        American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease.
        Endocr Pract. 2017; 23: 1-87

      Biography

      Jill S. Buterbaugh, DNP, FNP-BC, CNE, CME, is an associate professor of nursing at Frostburg State University in Frostburg, MD, and can be contacted at [email protected] .